PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to $20 at Needham & Company
Tweet
Share
E-mailGet Alerts PHAS Hot Sheet
Price: $0.07 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Join SI Premium – FREE
Needham & Company analyst Chad Messer raised the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $20.00 (from $18.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baidu (BIDU) PT Lowered to $150 at Benchmark on Near-Term Margin Concerns
- Needham on Klarna (KLAR): 'Shares Back to the Penalty Box'
- Palo Alto Networks (PANW) PT Raised to $390 at UBS, Neutral Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
